Shivom Roadmap_2019

Shivom Roadmap, Release Strategy & Status Update for 2019

Shivom Roadmap_2019

The march of time is relentless and as we start the second quarter of 2019, now is a good time to share some latest updates on Shivom’s roadmap, our evolving blockchain-based genomics & bio datahub and secure-storage and sharing platform, new partnerships and other developments pertaining to the Shivom ecosystem and OMX token.

Our Mission is Unchanged

The Shivom platform involves complex computer science and bioinformatics challenges. We aim to develop novel applications and a next-generation health information exchange and ecosystem which enables direct to consumer (“DTC”), pharma, clinical organizations, enterprises and others to provide customized health insights, therapies & care; and importantly to empower all individuals to own, manage and derive insights from their unique personal biodata in order to better manage their health and wellness. Collectively, we seek to work with all stakeholders to solve the various problems and inefficiencies the industry is facing at this period in time. If successful, our platform and technology solutions will not only lay the foundation for redefining the clinical research and drug discovery landscape but will also empower individuals to proactively manage their health and maintain control over their sensitive healthcare data. Ultimately, Shivom will be instrumental for helping to usher in a new era of precision medicine. Our mission remains unchanged.

MVP Release: Expected Features and Timeline

To deliver our vision, Shivom must hit key milestones and targets. The first key milestone is our MVP, which will demonstrate that data owners can securely store and share health and genomic and other “Omics” data; additionally, initiate an audit trail of data usage and activity based on our dynamic consent and permission features and traceability via the Ethereum blockchain. Enterprise customers such as pharmaceutical and institutional organisations will be able to search datasets based on various parameters, enter into a smart contract with data owners to utilize such data for clinical purposes and be able to run complex bioinformatic pipelines against big data without leaving Shivom’s platform. We remain confident in our abilities as researchers, engineers and operators to deliver on this milestone and key features as expected for our upcoming MVP release.  

We continue to scale up our development team in order to stay on track and reach our MVP milestone, which we plan to release by month-end June 2019. This version of our platform will include full traceability on blockchain, marketplace 2.0, end-to-end data discovery and analysis solution for enterprise customers and more. The requirements we have set include that it must clearly demonstrate traceability via Ethereum blockchain and enterprise customers running complex bioinformatic pipelines against big data without leaving the platform. From launch, the platform must be adaptive and be able to scale. Some features such as blockchain traceability, dynamic consent, updated user creation and login, however, will be offered in an interim release prior to the MVP. This next release will also include an updated marketplace with new products & services offered by our new DTC and telegenetic partners.

New Partners, Affiliates & Customers

Part of our roadmap will include onboarding of select DTC partners to be featured in our marketplace, which caters to consumers who wish to manage and improve their health and wellness within our blockchain- and token-based ecosystem. Our curated products will include select genetic and other testing kits, health reports, telemedicine services and more. For enterprise customers, our clinical platform will feature free and premium pipelines such as GWAS, Plink, Deep Variant and more. Additionally, researchers will have the ability to import their own pipelines from GitHub and in further updates following the MVP will be able to promote them in the marketplace and earn residual income through the use of our OMX tokens.

With these milestones in mind, this month we announced an exciting collaboration with Family Care Path (“FCP”), a spinoff company from world-renowned Cleveland Clinic. FCP maintains a genetic counsellor network and is offers proprietary web-based clinical decision support applications. The pilot for this collaboration will enable Shivom customers to access the FCP MyLegacy application and schedule a virtual genomic counselling session based on genomics and other personal healthcare and family data. We believe this service will be essential and provide much-needed guidance and clarity for our customers and are thrilled to be working with FCP, who are experts and thoughts leaders in the space. To read more about this collaboration visit the press release here.

We also onboarded Living DNA’s 3-in-1 Ancestry kit, which provides consumers with the ability to trace their origins back via maternal ancestors and see how they moved around the world over thousands of years. We are pleased to offer Living DNA as our first ancestry kit given the company’s scientific roots (the company is a collaboration of over 100 world-leading scientists, academic researchers and genetic experts from across the globe) and its relationship with DNA Worldwide Group, described as UK’s most advanced testing platform covering DNA, Drug, Alcohol and Forensic services. The company’s DNA kits are also based on a review of a significantly higher number of DNA markers then comparable lab testing companies; helping to ensure better results. As important, the company maintains strict privacy and security practices, which we require from all of our select partners and customers. To read more about this collaboration visit the press release here.

In addition to other D2C options, we are also working to onboard initial enterprise customers to include academic institutions and pharmaceutical companies. Given the requirements, our project is one of the more complex around the blockchain market today. Our task is difficult, but we are succeeding in our mission and progressing further every day. In parallel, we are also currently developing complementary projects with select partners that haven’t been announced as of yet. It is too early to release many details now but exciting things are happening both with respect to the kind of projects being pursued and the organizations now coalescing around the Shivom ecosystem.  Stay tuned to our Telegram announcements channel for further updates.

Shivom-Branded Products

You may have seen on our website and digital channels we announced our newest addition to our Shivom Innovation Council (“SIC”), Lion Martinez. Lion is a former national and European-level athlete, who has numerous national gold medals (in 100-metre sprint) in his kitty. He was also the youngest-ever Swedish to have participated in the 2002 European Championships in Munich. Lion holds a 100-metre world championship gold medal (2016) and has numerous records and medals (in 60, 100 and 200-metre sprints) to his credit. Additionally, he has been involved in coaching, public speaking and widespread health issues and initiatives over the past 20 years, engaging with children, youth, adults and senior citizens alike.

We are working closely with Lion and other stakeholders to develop an athletics/performance clinical program and other sports-related initiatives to include the development of Shivom-branded athletics products. The sports initiative in cooperation with our partners will use state-of-the-art genomics and analytics to develop insights catered to pro athletes in order to help make them fitter and perform on a higher level.  Our first product “The Complete Athletic Body Systems Report” will provide comprehensive performance related insights derived from multiple biological samples. We aim to unlock the secrets behind what makes an athlete … well, an athlete. We anticipate that our multi-part test will provide deep insights and help the pro user/elite athlete to better understand their body so that they can reach peak performance, reduce the risk of injury and recovery time, and more. Stay tuned for more information on our upcoming pro athletic products.

KuCoin & Exchange Updates

As some of you may be aware, our OMX token has been marked for special treatment on KuCoin for little over a month now. Despite our efforts and progress, trading volume remains low; accordingly, we are unlikely to meet Kucoin’s firm KPI requirement. Taking all factors into consideration to include our latest timelines and the increasingly limited support from the exchange, we have decided to focus our energies and resources on our existing and other prospective exchanges. Accordingly, we plan to pull out of KuCoin Exchange by 15 May 2019. Consequently, it’s imperative that all OMX holders with a balance/account in KuCoin plan accordingly and move their OMX token holdings to another appropriate exchange or secure wallet in a timely manner to avoid any potential complications. We highly recommend that any such individuals take appropriate action and transfer OMX holdings by 06 May 2019. Aside from KuCoin, OMX is currently traded on CoinBene, CoinSuper and IDEX. Our supported wallets include Jaax and Coinomi.


Announcements & Messaging Channels

On April 30th, we announced going live on Blockfolio Signals and Delta Direct. Our Director of Marketing and CEO will be providing updates on the project and token via these portfolio management applications along with our Telegram announcements channel. You may have well noticed we are in the process of moving away from our Telegram supergroup and pushing our active audience to our announcements channels, which will enable better, more targeted communications and excludes the numerous bots associated with the current supergroup. With this in mind and based on feedback received to date, we plan to phase out our supergroup in the coming months and ask our community members to join our new announcement channels in order to continue to get the latest project and token updates. We will give proper notice to our subscribers well in advance to ensure continuity of communications.

Looking Ahead

The next few months will be very exciting for the project. In addition to our scheduled MVP release, we have many other news and announcements to share as we continue to execute and focus on developing our applications & solutions and building the Shivom ecosystem. We look forward to keeping you updated on all and advancing the mission. As always, the entire Shivom team would like to thank everyone for their interest in the project, patience and continued belief in our team, technology and vision. We are also grateful for our early partners and their support and commitment to the project. As always, onwards and upwards!

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

Recommended

Ancestry Kit_Living_DNA_Shivom

Shivom Adds Living DNA to the Marketplace, Offering Customers a 3-in-1 ancestry Kit

Ancestry Kit_Living_DNA_Shivom

Living DNA’s 3-in-1 ancestry kit will provide Shivom’s customers with the ability to trace their origins back via maternal ancestors, and see how they moved around the world over thousands of years.

London, United Kingdom – April 15, 2019 – Shivom, a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, has now been approved as an affiliate of Living DNA. Through this affiliation, Shivom will redirect customers to the Living DNA website in order to purchase their 3-in-1 ancestry kit.

The ancestry kit which has been developed by Living DNA enables consumers to discover their ancestry from around the world via a simple cheek swab, providing exceptional regional details. Many of their customers have used this opportunity to travel to their ancestral homelands. Living DNA can show you your recent family ancestry covering up to 15 generations, and your deep ancestry with Motherline and Fatherline (if male) results. Additionally, the company have developed an improved Single nucleotide polymorphisms (SNP) genotyping platform that has been tailored to match the technical requirements of the different statistical methodologies they use to analyse customer data. Sirius, the new chip, has been designed using the Axiom® technology from Affymetrix / Thermo Scientific, which allows great flexibility to match every feature of the chip to their products.

“We are excited to offer Living DNA’s kits within our marketplace. Living DNA, along with parent company DNA Worldwide Group, shares the same high standards of excellence and commitment to consumer data ownership and security as Shivom. Living DNA’s kit is not only rated one of the best ancestry kits on the market, but they are also accredited and certified by leading international standards.” Says Henry Ines, CEO of Shivom.

For more information about Shivom please visit:
https://www.shivom.io

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

About Living DNA
Living DNA is a high definition of DNA testing that challenges the concept of race and tackles ideas of separation through our ‘One Family, One World’ education programmes. With 75% of clients living overseas, we do this globally.

Presenting self-truth and letting science talk helps people change their lives. Putting ancestry into context allows people to celebrate not only how unique they are but also understand how we are all connected going back through history.

For more information about Living DNA please visit:
www.livingDNA.com

Recommended

Cleveland Clinic-Family-Care-Path-Shivom

Shivom Partners with Family Care Path a Spin-Off Company from Cleveland Clinic

Cleveland Clinic-Family-Care-Path-Shivom

Family Care Path’s clinically-validated MyLegacy and CarePathConnect application will provide new ways for Shivom’s customers to take action on their genetic risk for certain hereditary conditions.

London, United Kingdom – April 2, 2019 – Shivom, a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, and Family Care Path (FCPI), a spin-off company from Cleveland Clinic adapting and marketing web-based clinical decision support applications, are collaborating to integrate FCPI’s MyLegacy application within Shivom’s marketplace. Through collaboration, Shivom’s customers can gain access to a personalised health risk profile and genomic counselling sessions which provide end-users with coaching to take proactive steps against hereditary conditions found within their genetic data.

FCPI has established an international telegenetic counselling network, branded CarePathConnect, which provides patients with the ability to privately and securely discuss their genetic health risk conditions with genetic counsellors and learn about the benefits and limitations of genetic testing via a HIPAA-compliant web-based video platform. The company exclusively licensed the family history collection and disease risk assessment tool from Cleveland Clinic, branded MyLegacy, which uses proprietary algorithms based on practice guidelines developed by the Cleveland Clinic Genomic Medicine Institute.

“Access to your genetic information is really just the beginning — using that information in combination with genetic counselling allows the necessary preventative measures to prevent serious health complications,” said Henry Ines, CEO of Shivom. “Our collaboration with Family Care Path enables Shivom’s customers to access their genetic information using a clinically validated programme to help them make lifestyle changes which seek to prevent or suppress hereditary conditions.”

The pilot for this collaboration will enable Shivom customers to access the FCP MyLegacy application and schedule a virtual genomic counselling session. Both clinical and non-clinical counselling sessions will be explored and processes will be established to ensure that customers are able to utilise both data collected from the FCP risk assessment tool as well as any genomic or other ‘omics’ reporting facilitated by Shivom subject to patient consent and permissions. Shivom also plans to arrange for its OMX token to be utilised as a means of payment and incentives for accessing counselling sessions and related services. The partnership marks a critical step in the roadmap for Shivom as it onboards key partners and services on its platform/marketplace to further demonstrate utility for its token.

“We are excited to collaborate with Shivom on this innovative effort. Working with Shivom will help their customers have a deeper understanding of their genetic information through testing, counselling and the ties to family health history” says David McKee, President and CEO of Family Care Path.

For more information about Shivom’s direct-to-consumer solutions please click here

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Shivom Social Channels:
● Official Homepage: shivom.io
● Twitter (English): @projectshivom
● Youtube: Shivom’s Channel
● Telegram: Shivom Announcements
● Facebook: @projectshivom
● Instagram: @projectshivom
● Medium: Shivom Official
● LinkedIn: @projectshivom

About Family Care Path
Family Care Path develops, adapts and markets web-based clinical software applications designed to improve patient outcomes, increase physician and clinical process efficiency, and interface with a variety of electronic health records.

Many exciting concepts for healthcare applications remain isolated within the development environment. Our company’s mission is to identify these opportunities and develop software solutions utilising industry standard protocols, to enable widespread adoption.

We utilise the latest technology to develop secure and scalable applications to improve the quality of healthcare and reduce cost. Leveraging industry standard technologies such as Microsoft Cloud and both the SMART® and HL7® FHIR® open standards, Family Care Path creates applications which can seamlessly communicate with all electronic health record systems.

For more information about Family Care Path please visit:
www.familycarepath.com

Recommended